Prophylactic administration of obinutuzumab, a B-cell-depleting antibody, reduces the incidence of corticosteroid-requiring chronic graft-vs-host disease (cGVHD) at 1 year from 35.2% to 13.3% in ...

Indications span MF and PV in adults, plus acute/chronic GVHD in patients ≥12 years, positioning XR as a once-daily ...

Amandeep Salhotra, MD, discusses preclinical findings that could support the addition of a BCL2 inhibitor to address acute or ...

Graft-versus-host disease (GVHD) is a life-threatening condition that can occur after an allogeneic stem cell transplant, which is a procedure that some blood cancer patients choose as it may offer ...

Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, ...

Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...

The approval is supported by bioequivalence data assessing the once-daily extended-release formulation to twice-daily immediate-release ruxolitinib in healthy participants.

Global Graft Versus Host Disease (GvHD) Treatment Market · GlobeNewswire Inc. Dublin, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease (GvHD) Treatment Market Report 2024" report has ...

What is Graft versus Host Disease? This condition typically occurs during a stem cell or bone marrow transplant from another individual. GvHD occurs when lymphocytes (immune cells) in the donor tissue ...

Hutchinson Center researchers have developed a new drug therapy that significantly reduces death from gastrointestinal graft-vs.-host disease in allogeneic stem-cell transplant patients. By adding a ...

SEATTLE — With increasing survival rates after allogeneic hematopoietic stem cell transplantation (HSCT) in children, dermatologists may be seeing more skin conditions associated with HSCT, including ...

Donor lymphocyte infusion (DLI) exerts a GVL effect, but its use is limited by a high incidence of GVHD. We retrospectively evaluated the efficacy of administering short-term immunosuppressive agents ...